2011 - ISBTS 2011 Symposium


Plenary Session II: Physiology & Mucosal Biology + Oral Communications 8

10.208 - Influence of triple and double immunosuppressive therapy on proinflammatory gene expression during acute cellular rejection episodes

Presenter: Martin, Rumbo, La Plata, Argentina
Authors: A. Zambernardi1,2, A. Chiodetti1, D. Meier2, E. Schiffrin3, A. Cabanne2, F. Nachman2, C. Rumbo2, G. Gondolesi2, M. Rumbo1


208
Influence of triple and double immunosuppressive therapy on proinflammatory gene expression during acute cellular rejection episodes

A. Zambernardi1,2, A. Chiodetti1, D. Meier2, E. Schiffrin3, A. Cabanne2, F. Nachman2, C. Rumbo2, G. Gondolesi2, M. Rumbo1

1Laboratorio de Investigaciones del Sistema Inmune (LISIN), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina; 2Instituto de Transplante Multiorgánico, Hospital Universitario Fundación Favaloro (HUFF), Buenos Aires, Argentina; 3NestlĂ© Research & Development Center, Vers Chez Les Blancs, Switzerland

Introduction: Acute cellular rejection (ACR) is the first cause of graft loss after intestinal transplant. A better understanding of the process and an improvement of the diagnostic tools available are desirable. With this aim, we analyzed by q-PCR the relative expression of the proinflammatory genes: gamma interferon (IFNG), CXCL11, CXCL10, CCL20, and MXA in graft follow-up biopsies.

Material and Methods: A total of 82 samples of 15 patients (10 pediatrics/5 adults) were analyzed. Among them, 39 showed normal histopathology and clinical condition, 20 corresponded to rejection episodes diagnosed by histopathology and the remaining 23 to different clinical conditions (abdominal collections, enteritis, non abdominal infections and others). Considering the immunosuppressive (IS) therapy at the time of sampling, two groups were identified: dual therapy (corticosteroid and tacrolimus, n=35) or triple therapy (adding sirolimus or mycophenolate mofetil, n=47). Expression of β-actin was used as normalizer and relative expression was calculated using the group of normal samples as reference.

Results: Considering the clinical condition, none of the genes showed a specific increase of expression, since increments were detected either in rejection, infection, or other inflammatory conditions. However, expression of IFNG, CXCL11 and CXCL10 correlated with the severity of the ACR episodes (Table 1). The increment of IFNG gene expression alone was associated to lymphocytes and plasma cells infiltration in the lamina propria (IFNG, p<0.001). Expression of IFNG was modulated by the immunosuppressive treatment; this was especially evident in samples with mild ACR, patients under triple IS showed lower IFNG and CXCL10 than those under double IS (p<0.001 and p<0.025 respectively).

Gene ± SE

Asymptomatic ACR

Mild /moderate ACR

Severe ACR

IFNG

3.0 ± 1.3

5.9 ± 2.7

8.3 ± 4.3

CXCL10

2.1 ± 0.7

5.6 ± 2,0

18.9 ± 13.5

CXCL11

1.3 ± 0.5

7.7 ± 4,7

11.4 ± 3.8

Table I: Relative expression calculated using the group of normal samples as reference.

Conclusions: Gene expression analysis is a valuable tool to understand the biological processes ongoing during ACR. IS therapy modulates IFNG and CXCL10 gene expression. The analysis of a larger number of samples and inclusion of new genes will improve the characterization ACR process.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi